Facet Biotech (NASDAQ:FACT.DL)

CAPS Rating No stars 
FACT.DL VS S&P 500 (SPY)

FACT.DL News and Commentary

This ticker is not currently Ratable.

Motley Fool CAPS is a community working together to find better stocks and to become better investors.
Powered by: CAPS

All Players

0 Outperform
0 Underperform
 

All-Star Players

0 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

FACT.DL Summary

  • Sector:
  • Industry:
  • Tags:

Top FACT.DL Bull/Bear Pitches

fdude71 (73.13)
Submitted February 25, 2010

Very successful fund Baupost owns Facet Biotech (FACT). Facet is a $420 million market capitalization biotech company. A classic value-investor setup that was a spinoff from parent PDL Biopharma (PDLI) in December 2008. Facet contains the former R&D… More

gmxBatteringRam (30.11)
Submitted June 22, 2009

Repost of a blog.Examining Facet BiotechQ: There's been a lot of talk about Facet Biotech (FACT). Why is this company generating discussion?A: Facet is the spinoff of PDL Biopharma (PDLI), which was created to give investors a shot at PDL's drug… More

Fools bearish on FACT.DL
are also bearish on:

Featured Broker Partners


Advertisement